SER-109 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Clostridium Difficile

Conditions

Clostridium Difficile

Trial Timeline

May 1, 2015 → Oct 1, 2016

NCT ID

NCT02437487

About SER-109 + Placebo

SER-109 + Placebo is a phase 2 stage product being developed by Seres Therapeutics for Clostridium Difficile. The current trial status is completed. This product is registered under clinical trial identifier NCT02437487. Target conditions include Clostridium Difficile.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03183128	Phase 3	Completed	Jul 10, 2017	Sep 29, 2020	Clostridium Difficile Infection
NCT02437487	Phase 2	Completed	May 1, 2015	Oct 1, 2016	Clostridium Difficile

Competing Products

20 competing products in Clostridium Difficile

See all competitors

Product	Company	Stage	Hype Score
Fidaxomicin + Vancomycin + Placebo	Astellas Pharma	Approved	85
Fidaxomicin + Treatment for CDI other than fidaxomicin Type	Astellas Pharma	Pre-clinical	23
OPT-80 + vancomycin	Astellas Pharma	Phase 3	77
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules	Astellas Pharma	Phase 3	77
Fidaxomicin + Vancomycin	Astellas Pharma	Approved	85
Fidaxomicin + Vancomycin	Merck	Approved	85
fidaxomicin + Placebo	Merck	Phase 3	77
Surotomycin + Placebo	Merck	Phase 1	33
CB-183,315 + Placebo + Vancomycin	Merck	Phase 2	52
Surotomycin + Placebo	Merck	Phase 1	33
MK-6072 + MK-3415A + Placebo + SOC	Merck	Phase 3	77
Vancomycin + Fidaxomicin	Merck	Approved	85
Fidaxomicin	Merck	Pre-clinical	23
Bezlotoxumab + Standard CDI treatment	Merck	Pre-clinical	23
MK-3415 + MK-6072 + MK-3415A + Placebo + SOC	Merck	Phase 3	77
Fidaxomicin + Vancomycin + Matching Placebo to Fidaxomicin	Merck	Phase 3	77
bezlotoxumab + Vancomycin Oral	Merck	Approved	85
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)	Merck	Phase 3	77
Bezlotoxumab Injection [Zinplava]	Merck	Pre-clinical	23
PAR-101/OPT-80 + Vancomycin	Merck	Phase 3	77

Other Products from Seres Therapeutics

SER-109 + PlaceboPhase 3

SER-109Phase 3

Vancomycin Pre-Treatment + Placebo for Vancomycin Pre-Treatment + SER-287 + Placebo for SER-287Phase 2

Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401Phase 1

SER-262 + PlaceboPhase 1